Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Weight loss · United States
Peptides for weight loss: which are approved, what the trials show, and what they cost
The peptides with FDA approval for weight management, and the largest published trials, are the GLP-1 medicines semaglutide (Wegovy) and tirzepatide (Zepbound).[1][3] Several newer peptides, such as retatrutide, CagriSema and survodutide, are still in trials. Others marketed for fat loss, such as AOD-9604 and MOTS-c, have no FDA approval for it. This guide sets out the status of each, what the trials reported, and what the approved options cost today.
Weight loss peptides at a glance
| Medicine | What it is | FDA status for weight loss | Can you get it in the US? |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 receptor agonist, a peptide. Weekly injection or daily pill | FDA approved for chronic weight management: injection June 4, 2021; pill December 22, 2025[1][2][16] | Yes, on prescription: brand-name Wegovy, or compounded semaglutide (compounded medicines are not FDA approved) |
| Tirzepatide (Zepbound) | GLP-1 and GIP receptor agonist, a peptide. Weekly injection | FDA approved for chronic weight management, November 8, 2023[3][16] | Yes, on prescription: brand-name Zepbound, or compounded tirzepatide (not FDA approved) |
| Liraglutide (Saxenda) | GLP-1 receptor agonist, a peptide. Daily injection | FDA approved for obesity, December 23, 2014[4] | Yes, on prescription |
| Orforglipron (Foundayo) | Not a peptide: Lilly describes it as a small molecule (non-peptide) GLP-1 receptor agonist. Daily pill | FDA approved for weight reduction and maintenance, April 1, 2026[6][5] | Yes, on prescription |
| Retatrutide | GIP, GLP-1 and glucagon receptor agonist, a peptide. Weekly injection | Investigational. Not approved for any use; Lilly plans to file with the FDA in Q1 2027[10][15] | No. Products sold online as "research" retatrutide are unapproved drugs |
| CagriSema (cagrilintide and semaglutide) | An amylin analog combined with semaglutide. Weekly injection | Not FDA approved. Novo Nordisk announced its New Drug Application on December 18, 2025[11] | No, outside clinical trials |
| Survodutide | GLP-1 and glucagon receptor agonist, a peptide. Weekly injection | Investigational, in Phase 3 trials. Not approved[12] | No, outside clinical trials |
| Tesamorelin (Egrifta) | Growth hormone releasing hormone analog, a peptide | FDA approved in 2010 only to reduce excess abdominal fat in adults with HIV and lipodystrophy. Not approved for general weight loss[13] | On prescription for its approved use |
| MOTS-c | A mitochondrial peptide researched for metabolism | Not FDA approved for any use. One of six peptides in the HHS interim compounding policy of October 30, 2026, which is not an approval[14] | Only as a compounded product under that interim policy, on prescription |
| AOD-9604 | A fragment of human growth hormone marketed for fat loss | Not FDA approved for any use, and not in the HHS interim compounding policy[14] | No approved or policy-covered route |
What the trials reported
These are the headline results each source reports. The trials enrolled different people for different lengths of time, so the figures cannot be compared as if the medicines were tested against each other.
- Semaglutide 2.4 mg (STEP 1, 1,961 adults, 68 weeks): Average weight change about minus 14.9%, against minus 2.4% with placebo.[7]
- Tirzepatide, highest dose (SURMOUNT-1, 72 weeks): Average weight loss 20.9%, against 3.1% with placebo.[8]
- Retatrutide, highest dose (investigational) (TRIUMPH-1, 80 weeks): Average weight loss 25.0%, against 3.9% with placebo (treatment-regimen estimand).[9]
- Survodutide (investigational) (SYNCHRONIZE-1, 76 weeks): Up to 16.6% average weight loss, against 3.2% with placebo.[12]
Non-prescription and “research” peptides
No FDA-approved weight loss peptide is sold without a prescription. Peptides sold online “for research use”, including retatrutide and semaglutide, are unapproved drugs, and the FDA has warned sellers of them.[15][16] The HHS compounding policy of October 30, 2026 covers six peptides, including MOTS-c, for compounding on a prescription; it is not an FDA approval and it does not cover retatrutide, semaglutide research products or AOD-9604.[14] For what that policy does cover, see how BPC-157 and the other five peptides can be prescribed.
What weight loss peptides cost
- Wegovy, brand name: $149 a month for the pill and $199 a month for the pen at NovoCare Pharmacy, Novo Nordisk's own self-pay pharmacy (checked November 19, 2026). See Wegovy cost without insurance.
- Zepbound, brand name: from $299 a month at LillyDirect, Lilly's own self-pay pharmacy (checked November 19, 2026). See Zepbound cost without insurance.
- Compounded tirzepatide: $69 to $399 a month on a month to month plan across 13 US online programs (checked November 19, 2026).
- Compounded semaglutide: the lowest price we track is $39 a month for compounded semaglutide at welludr, an advertised sale price, checked November 19, 2026.
The table below lists every compounded GLP-1 price we track, read daily from each provider's own page and dated. A prescription is a clinician's decision after an online review, never guaranteed.
| # | Provider | Price | What the price is | Current offer | Checked | Link |
|---|---|---|---|---|---|---|
| 1 | welludrsemaglutide | $39/mo | Starting at, advertised sale price, per monthPage wording: BLACK FRIDAY SALE DISCOUNT APPLIED $39 /mo Semaglutide $69 /mo Tirzepatide | New Customer Offer: $150 off for LifeOffer end date not stated | See pricing | |
| 2 | Embodysemaglutide | $49/mo | advertised sale price, per monthPage wording: PRE-BLACK FRIDAY SALE DISCOUNT APPLIED! $49 Semaglutide / $99 Tirzepatide | PRE-BLACK FRIDAY SALE DISCOUNT APPLIED!Standard price | See pricing | |
| 3 | REBLsemaglutide | $55/mo | From, ongoing monthly pricePage wording: Treatments from $55/mo | None recorded | ||
| 4 | Collectivesemaglutide | $59/mo | ongoing monthly price; plus a required $199 annual membershipPage wording: Compounded Semaglutide $59/mo. Same price, any dose. | None recorded | See pricing | |
| 5 | SnagRxsemaglutide | $59/mo | advertised sale price, per monthPage wording: PRE-BLACK FRIDAY SALE DISCOUNT APPLIED! Semaglutide for $59 / Tirzepatide for $109 | PRE-BLACK FRIDAY SALE DISCOUNT APPLIED!Standard price | See pricing | |
| 6 | Arborsemaglutide | $89/mo | From, ongoing monthly pricePage wording: Semaglutide From $89/mo | None recorded | See pricing | |
| 7 | Yucca Healthsemaglutide | $89/mo | From, ongoing monthly pricePage wording: Monthly Plan Billed monthly · no commitment $89 /mo was $146/mo | None recorded | Paused: not currently accepting new patients through our links. See alternatives | |
| 8 | bmiMDsemaglutide | $99/mo | Starting as low as, ongoing monthly pricePage wording: Compounded Semaglutide Starting as low as $99/mo | None recorded | See pricing | |
| 9 | Eden Healthsemaglutide | $99/mo | ongoing monthly pricePage wording: Semaglutide $99 /mo | None recorded | See pricing | |
| 10 | GobyMedssemaglutide | $99/mo | Starting at, per month on a prepaid plan: 3-month starter bundle, $299 billedPage wording: Starting at $99/m Compounded Semaglutide 3-Month Starter Bundle ... Total $299 | None recorded | See pricing | |
| 11 | Trimisemaglutide | $99/mo | per month on a prepaid plan: 12-month plan, $1,188 billedPage wording: 12 months Lowest rate $99/mo $1,188 billed upfront | None recorded | Paused: not currently accepting new patients through our links. See alternatives | |
| 12 | Strut Healthsemaglutide | $129/mo | ongoing monthly pricePage wording: SEMAGLUTIDE INJECTABLE $129 Monthly vial | None recorded | See pricing | |
| 13 | Healthy Living Clinictirzepatide | $149 | price per 4 weeks for 3 mg to 9 mg a week; ships as a 12-week box paid in 3 payments, one every 4 weeks, and all 3 are due once the box shipsPage wording: Tirzepatide - Intermediate Dose $149.00 /4weeks | None recorded | See pricing | |
| 14 | TMatessemaglutide | $158/mo | per month on a prepaid plan: 12 months, $1,900 billedPage wording: 12 Months$158/mo Save 37% $1900 | None recorded | Paused: not currently accepting new patients through our links. See alternatives | |
| 15 | Bodybuilding.com GLP-1semaglutide | $159.33/mo | per month on a prepaid plan: 3-month bundle, $478 billedPage wording: $159.33/mo on 3-month bundle | First month $179 (standard | See pricing | |
| 16 | MEDVitirzepatide | $166/mo | advertised sale price, per monthPage wording: Friday Sale: Tirzepatide only $166/mo | Friday SaleOffer end date not stated | See pricing | |
| 17 | MEDGmsemaglutide | $169/mo | per month on a prepaid plan: 12-Month Supply, $2,028 billedPage wording: 12-Month Supply Billed every 12 months $2,028 $169/mo | None recorded | See pricing | |
| 18 | Sprout Healthsemaglutide | $169/mo | Starting at, ongoing monthly pricePage wording: Compounded semaglutide Starting at $169/mo | None recorded | See pricing | |
| 19 | Shedsemaglutide | $175/mo | Starting at, ongoing monthly pricePage wording: BLACK FRIDAY PRICE LOCKED FOREVER Compounded Semaglutide $175 /mo was $199 Billed as $350 every 2 months | None recorded | See pricing | |
| 20 | Fridaystirzepatide | $198/mo | As low as, advertised sale price, per monthPage wording: Tirzepatide: As low as $198/mo | PRICE LOCKED IN FOREVEROffer end date not stated | See pricing | |
| 21 | Luvo Healthsemaglutide | $209 | price per 4 weeks, billed every 4 weeksPage wording: 4 weeks of injections, delivered every 4 weeks. $209 from your second delivery. | None recorded | See pricing | |
| 22 | PeterMDtirzepatide | $249/mo | ongoing monthly pricePage wording: Then $249 per month • billed quarterly • 60mg | None recorded | See pricing | |
| 23 | Foundsemaglutide | $289/mo | ongoing monthly pricePage wording: Compounded semaglutide 1 month $199/mo $289/mo | None recorded | See pricing | |
| 24 | Wellorithmsemaglutide | $299/mo | ongoing monthly pricePage wording: Compounded semaglutide ongoing (every month) $299 | First month $179Offer end date not stated | See pricing |
Source: FDA: Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) · United States · Decision February 21, 2025
Source: FDA: Federal Register notice — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B · United States · Published May 1, 2026
For every price in one place, see the US GLP-1 price index; to choose a program by what matters to you, see the best online GLP-1 programs by use case.
Frequently asked questions
What is the best peptide for weight loss?
There is no single best one for everyone; that is a decision for a licensed clinician. The peptides with FDA approval for weight management and the largest published trials are semaglutide (Wegovy) and tirzepatide (Zepbound), both GLP-1 medicines. Peptides such as AOD-9604 and MOTS-c are marketed for fat loss but have no FDA approval for it.
Are there non-prescription peptides for weight loss?
No FDA-approved weight loss peptide is sold without a prescription. Products sold online as "research" peptides, including retatrutide and semaglutide, are not approved medicines, and the FDA has issued warning letters to sellers of them.
Is semaglutide a peptide?
Yes. Semaglutide, tirzepatide and liraglutide are peptides. Orforglipron (Foundayo), Lilly's GLP-1 pill, is not: Lilly describes it as a small molecule, non-peptide medicine.
How much do weight loss peptides cost?
Brand-name Wegovy starts at $149 a month from Novo Nordisk's own pharmacy. Brand-name Zepbound starts at $299 a month from LillyDirect. Compounded tirzepatide costs $69 to $399 a month on a month to month plan across the US online programs we track. The lowest compounded semaglutide price is $39 a month for compounded semaglutide at welludr, an advertised sale price, checked November 19, 2026. Every figure is read from the seller's own page and dated; compounded medicines are not FDA approved.
Can I get retatrutide for weight loss?
No. Retatrutide is investigational and not approved for any use; Lilly plans to file with the FDA in the first quarter of 2027. The approved medicines in the same family that you can be prescribed today are tirzepatide and semaglutide.
For what the FDA has said about each peptide, see our guide are peptides safe.
Sources
Each numbered reference points to one of these. The date is the day we read the source; trial figures are quoted as the source reports them.
- FDA news release, June 4, 2021: FDA approves new drug treatment for chronic weight management, first since 2014 (Wegovy, semaglutide injection 2.4 mg once weekly), as republished by BioSpace. www.biospace.com. Read November 15, 2026.
- Drug Topics, December 23, 2025: Wegovy pill (oral semaglutide 25 mg) receives FDA approval for weight management (approved Monday, December 22, 2025). www.drugtopics.com. Read November 15, 2026.
- Drugs.com approval history: FDA approves Zepbound (tirzepatide) for chronic weight management, November 8, 2023. www.drugs.com. Read November 15, 2026.
- Drugs.com approval history: FDA approves Saxenda (liraglutide) for obesity, December 23, 2014. www.drugs.com. Read November 15, 2026.
- Eli Lilly press release, April 9, 2026: Foundayo (orforglipron), described as a once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, available in the US. investor.lilly.com. Read November 15, 2026.
- Fierce Pharma: FDA approval of Foundayo (orforglipron), announced by the agency on April 1, 2026. www.fiercepharma.com. Read November 15, 2026.
- American College of Cardiology trial summary, STEP 1 (Wilding JPH et al., New England Journal of Medicine 2021): semaglutide 2.4 mg in 1,961 adults with overweight or obesity over 68 weeks. www.acc.org. Read November 15, 2026.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022. pubmed.ncbi.nlm.nih.gov. Read November 15, 2026.
- Eli Lilly press release, May 21, 2026: TRIUMPH-1 topline results for retatrutide. investor.lilly.com. Read November 15, 2026.
- Eli Lilly press release, July 23, 2026: TRIUMPH-2 and TRIUMPH-3 results, and the plan to file retatrutide with the FDA in Q1 2027. lilly.gcs-web.com. Read November 15, 2026.
- Drugs.com development history: CagriSema (cagrilintide and semaglutide), FDA approved: No; New Drug Application announced by Novo Nordisk on December 18, 2025. www.drugs.com. Read November 15, 2026.
- BioPharm International, April 28, 2026: survodutide (investigational) SYNCHRONIZE-1 Phase 3 results, up to 16.6% average weight loss against 3.2% with placebo over 76 weeks. www.biopharminternational.com. Read November 15, 2026.
- Drugs.com approval history: Egrifta (tesamorelin), first FDA approved November 10, 2010, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. www.drugs.com. Read November 15, 2026.
- HHS Office of the Secretary, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", Docket No. HHS-OASH-2026-0496, Federal Register public inspection copy (published October 30, 2026). public-inspection.federalregister.gov. Read November 15, 2026.
- FDA warning letter to Prime Vitality, Inc. dba Prime Peptides, December 10, 2024: retatrutide and semaglutide sold online as "research" products are unapproved new drugs. www.fda.gov. Read November 15, 2026.
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss. www.fda.gov. Read November 15, 2026.
This page is information, not medical advice. It does not recommend any medicine and gives no dosing guidance. Talk to a licensed clinician about what is appropriate for you.